Amniotic Membrane Stem Cell Isolation Method
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and cultivating stem/progenitor cells, particularly epithelial cells, from umbilical cord sources are inefficient, ethically challenging, and burdensome for patients, lacking reliable sources for epithelial cell-based therapies such as skin resurfacing and liver repair.
Innovation Solution
A method involving the separation and culture of the amniotic membrane from the umbilical cord in vitro, allowing for the isolation and expansion of stem/progenitor cells with embryonic stem cell-like properties, including epithelial and mesenchymal cells, using techniques like enzymatic digestion and direct tissue explant, followed by differentiation and preservation for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical procedures are used to harvest stem cells from bone marrow or fat tissue, then stem cells can be obtained for therapy, but the procedure causes mental and physical burden to patients and requires invasive techniques with anesthesia
Solution Approach 1:
The invention extracts stem cells from umbilical cord blood and Wharton's jelly, which are discarded medical waste products after birth. This extraction approach converts waste material into a valuable therapeutic resource, eliminating the need for invasive surgical procedures on patients while providing a reliable stem cell source.
Solution Approach 2:
The invention uses umbilical cord blood and Wharton's jelly as intermediary materials that serve dual purposes: they are byproducts of normal birth procedures and contain abundant stem cells. These intermediaries bridge the gap between waste disposal and therapeutic resource acquisition without requiring additional patient intervention.
2Reliability
If mesenchymal stem cells are harvested from bone marrow or adipose tissue, then cells can be obtained for mesodermal defect repair, but the number of stem cells extracted is rather low
Solution Approach 1:
The invention extracts stem cells from umbilical cord blood and Wharton's jelly, which contain significantly higher concentrations of stem cells compared to bone marrow or adipose tissue. This extraction from underutilized sources resolves the yield limitation problem.
Solution Approach 2:
The invention changes the source parameter from traditional adult tissues (bone marrow, fat) to fetal-derived tissues (umbilical cord blood, Wharton's jelly). This parameter change results in a substantial increase in stem cell quantity and quality, providing sufficient cells for therapeutic applications.
3Adaptability or versatility
If embryonic stem cells are used for therapy, then unlimited differentiation potential is available, but ethical problems arise from their use
Solution Approach 1:
The invention extracts stem cells from umbilical cord blood and Wharton's jelly, which are fetal-derived but not embryonic. This extraction approach provides cells with high differentiation potential comparable to embryonic stem cells while avoiding the ethical controversies surrounding embryo destruction.
Solution Approach 2:
Instead of using embryonic stem cells and facing ethical objections, the invention inverts the approach by using fetal-derived stem cells from umbilical cord waste products. This inversion maintains the therapeutic benefits while eliminating the ethical harm.
4Quantity of substance
If stem cells are isolated from term umbilical cord blood, then haematopoetic stem/progenitor cells can be obtained, but mesenchymal stem/progenitor cells cannot be successfully isolated or cultured
Solution Approach 1:
The invention segments the umbilical cord into two distinct components: umbilical cord blood (for haematopoetic stem cells) and Wharton's jelly (for mesenchymal stem cells). This segmentation allows each component to be processed separately using optimized protocols, ensuring successful isolation of both cell types without cross-contamination or methodological limitations.
Solution Approach 2:
The invention uses Wharton's jelly as an intermediary tissue that specifically provides mesenchymal stem cells, complementing the haematopoetic stem cells obtained from umbilical cord blood. This intermediary tissue resolves the limitation of not being able to isolate mesenchymal cells from cord blood alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a reliable and ethically acceptable source of stem/progenitor cells for various applications in regenerative medicine, enabling efficient isolation and cultivation of epithelial and mesenchymal cells for therapeutic uses without posing a significant biomedical burden on patients.
Implementation Method 1
separating the amniotic membrane from the other components of the umbilical cord in vitro
Data Source
AI summary
The present invention relates to a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The isolated stem cell cells can have embryonic stem cell-like properties and can be used for various therapeutic purposes. In one embodiment, the invention relates to the isolation and cultivation of stem cells such as epithelial and/or mesenchymal stem/progenitor cells under conditions allowing the cells to undergo mitotic expansion. Furthermore, the invention is directed to a method for the differentiation of the isolated stem/progenitor cells into epithelial and/or mesenchymal cells.